Inclusion Criteria:  Patient who provided written signed informed consent prior to the first study-specific procedures. Patient who receives durvalumab for unresectable stage III NSCLC at first time following chemoradiation therapy Patient whose performance status showed 0 or 1 prior to durvalumab treatment Patient who is able and willing to wear the devices daily for up to 6 months as instructed  Exclusion Criteria:  Patient under immunotherapy treatment other than durvalumab. Patient had received prior immunotherapy Patient under the interventional clinical studies using unapproved drugs or off-label use of drugs Patient who showed ILD (including radiation pneumonitis) of Grade 2 and higher, after consolidated chemoradiation therapy. Patient who is judged as not suitable for the study by the study site investigators, in terms of fitting wearable devices, presence of silicone or metallic allergy